Board has recommended final dividend for the Financial Year 2025-26, subject to approval of shareholders.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 10.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health Ltd reported strong FY 2025-26 results with net profit of Rs. 32,691 lakhs, up 39% from Rs. 23,441 lakhs in the prior 9-month period. Revenue from operations grew to Rs. 140,797 lakhs from Rs. 93,417 lakhs. The Board recommended a final dividend of Rs. 45 per share (face value Rs. 10), aggregating Rs. 7,470 lakhs, subject to shareholder approval at the 59th AGM. Total dividend for FY 2025-26 amounts to Rs. 205 per share, combining the earlier interim dividend of Rs. 160 and a one-time special dividend. EPS for the year stood at Rs. 196.94. Note: The company changed its financial year-end from June 30 to March 31, making prior period comparisons only indicative.
The company delivered robust profit growth with a total dividend of Rs. 205 per share, signaling strong cash generation and shareholder-friendly policy. The final dividend is subject to AGM approval and will be paid on or before September 25, 2026.